Combination therapy

Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)

Retrieved on: 
Tuesday, April 9, 2024
Toxicity, PR, Combination therapy, VLS, MSI-H, PD, LFT, RDE, Duodenal cancer, Patient, Hypertelorism, Radiation, MCC, MDNA, AACR, TSX, DLT, Pancreatic cancer, Safety, Regulatory T cell, Melanoma, Cancer, BCC, NK, Pharmaceutical industry

March 22, 2024) include:

Key Points: 
  • March 22, 2024) include:
    Acceptable safety profile: No dose limiting toxicity (DLT) reported and no evidence of vascular leak syndrome (VLS).
  • A new lymph node lesion developed during a 8-week MDNA11 treatment break (vacation) was treated with a single course of radiotherapy prior to resumption of MDNA11.
  • A new lymph node lesion developed at week 16 while baseline target and non-target lesions remained stable or decreased.
  • Monotherapy expansion is continuing to enroll patients with metastatic melanoma, non-melanoma skin cancers (cSCC, MCC, and BCC) and MSI-H/dMMR tumors.

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Retrieved on: 
Thursday, April 4, 2024
HCC, Combination therapy, Nivolumab, Head, Patient, Bevacizumab, Therapy, Cancer, PD-1, Pharmaceutical industry

These earlier Phase 1 data complement the positive Phase 1b/2 data reported in October 2023 from a global randomized study of TPST-1120 in combination with atezolizumab and bevacizumab in first-line patients with advanced HCC, which showed clinical superiority of the TPST-1120 arm across multiple study endpoints and relevant biomarker-defined patient subpopulations.

Key Points: 
  • These earlier Phase 1 data complement the positive Phase 1b/2 data reported in October 2023 from a global randomized study of TPST-1120 in combination with atezolizumab and bevacizumab in first-line patients with advanced HCC, which showed clinical superiority of the TPST-1120 arm across multiple study endpoints and relevant biomarker-defined patient subpopulations.
  • “In this Phase 1 study of TPST-1120, we saw the first evidence of anti-tumor activity in multiple cancer types, affirming our belief that PPARα inhibition is an exciting and novel approach for cancer treatment,” said Sam Whiting, M.D., Ph.D., chief medical officer and head of R&D at Tempest.
  • “These early-phase data are supported by the positive top line results of the ongoing randomized Phase 1b/2 trial in first-line HCC.
  • We believe there is tremendous potential for TPST-1120 to make a meaningful impact for patients and we look forward to providing updated data this year.”

VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma

Retrieved on: 
Wednesday, April 3, 2024
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Toxicity, Combination therapy, SOC, Survival, Disease, Patient, GBM, Vaccine, Neoplasm, Decompression (diving), Safety, VBI, Pharmaceutical industry

The multi-center, randomized, controlled, open-label study has been designed to evaluate overall survival, tumor response rates, and safety and tolerability of VBI-1901 as a monotherapy in rGBM patients.

Key Points: 
  • The multi-center, randomized, controlled, open-label study has been designed to evaluate overall survival, tumor response rates, and safety and tolerability of VBI-1901 as a monotherapy in rGBM patients.
  • Dr. Anderson commented: “In recurrent GBM, tumors typically double or triple in size within six weeks, with no effective treatments available to improve survival.
  • Early indications from this ongoing study suggest tumor growth behavior in-line with expectations for both the standard-of-care arm and the VBI-1901 arm, based on positive data seen from the Phase 1/2a study.
  • As of March 22, 2024, 17 patients have been randomized 1:1 to either the active, VBI-1901 treatment arm, or to the control, standard-of-care treatment arm (SoC).

Avenacy Announces New Product Launches and Participation in DCAT Week 2024

Retrieved on: 
Monday, March 18, 2024
Biotechnology, General Health, FDA, Health, Pharmaceutical, HER2, Combination therapy, Fulvestrant, Growth, AstraZeneca, Entrepreneurship, DCAT, Merck, Merck & Co., Woman, Syringe, Breast cancer, Safety, Multimedia, Food, Injection, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240318415023/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240318415023/en/
    “Avenacy has had a strong start to 2024, with two product launches already executed and two more newly announced additions to our rapidly expanding portfolio.
  • Avenacy will begin shipping Fosaprepitant for Injection and Fulvestrant Injection to wholesale partners this week.
  • To learn more about Avenacy’s products or the Company’s exciting growth plans for 2024, please see the Avenacy management team at DCAT Week 2024 taking place in New York City from March 18-21st.
  • To request a meeting with a member of the Avenacy team, please reach out to [email protected] .

Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors

Retrieved on: 
Wednesday, March 6, 2024
Paper, Combination therapy, Breast cancer, SAN, Woman, FDA, Animal, Proteolysis targeting chimera, Behavior, Therapy, Selective estrogen receptor degrader, Enzyme inhibitor, CNS, Pharmacokinetics, Survival, MOA, Research, Mutant, Pharmaceutical industry

The paper, titled “Palazestrant (OP-1250), a Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination”, describes the scientific background underlying the design, discovery and optimization of palazestrant.

Key Points: 
  • The paper, titled “Palazestrant (OP-1250), a Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination”, describes the scientific background underlying the design, discovery and optimization of palazestrant.
  • “What’s even more exciting is to see how faithfully the pre-clinical research predicted the behavior of palazestrant now that it is in late-stage clinical development.
  • In mouse xenograft models, palazestrant demonstrated excellent pharmacokinetics, was well tolerated, showed synergy with CDK4/6 inhibitors, and was highly effective at reducing tumor growth in both wild-type and ESR1-mutant ER+ breast cancer.
  • In addition, in an ESR1-mutant intercranial xenograft model, palazestrant inhibited tumor growth and improved survival of animals with CNS metastases, even after stopping drug treatment.

Groundbreaking Food Allergy Treatment Research to Be Unveiled at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

Retrieved on: 
Monday, February 19, 2024
Combination therapy, Food allergy, MD, Omalizumab, FDA, Anaphylaxis, Access, Risk, Allergy

MILWAUKEE, Feb. 19, 2024 /PRNewswire-PRWeb/ -- Renowned allergist Dr. Robert A. Wood, MD FAAAAI, will present detailed findings from a Phase 3 clinical trial that will have significant impact in the world of food allergy on Sunday, February 25 during a late breaking symposium during the 2024 AAAAI Annual Meeting, in Washington, DC.

Key Points: 
  • Wood, MD FAAAAI, will present detailed findings from a Phase 3 clinical trial that will have significant impact in the world of food allergy on Sunday, February 25 during a late breaking symposium during the 2024 AAAAI Annual Meeting, in Washington, DC.
  • Following the presentation, members of the media will have an exclusive opportunity to engage in a question-and-answer session with Dr. Wood and key stakeholders involved in the study.
  • The late breaking symposium and subsequent media opportunity are open exclusively to registered members of the media.
  • For on-site registration, please proceed to the Press Room, located in the convention center, level 1, room 102A.

CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors Market to grow by USD 2.23 billion between 2023 and 2028, growth Driven by High target affinity and specificity of CTLA4 inhibitors - Technavio

Retrieved on: 
Friday, January 26, 2024
Bristol Myers Squibb, Cytotoxicity, Research, Incidence, Melanoma, ROW, Biotechnology, AstraZeneca, Ipilimumab, HDAC, Carcinoma, Bone marrow suppression, Growth, BioNTech, Bio-Techne, NSCLC, Combination therapy, Investment, Disease, BMS, USD, FDA, Diarrhea, HBM, Hair loss, Merck, CTLA4, Immune system, Pharmaceutical industry

NEW YORK, Jan. 25, 2024 /PRNewswire/ -- The CTLA4 (cytotoxic t-lymphocyte-associated protein 4) inhibitors market is estimated to grow by USD 2.23 billion from  2023 to 2028, growing at a CAGR of 15.11%. High target affinity and specificity of CTLA4 inhibitors are notably driving the growth. Despite several approved therapies, the treatment landscape for advanced or recurrent cancer lacks sufficient drug responsiveness. Available therapies often lead to severe side effects, reducing patient compliance. Chemotherapy, the current standard of care for advanced cancers, causes significant adverse effects like bone marrow suppression, diarrhea, and hair loss. Similarly, surgery and radiation therapy have limitations in treating recurring carcinomas like melanomas. Furthermore, CTLA4 inhibitors work by enhancing the immune system, resulting in comparatively fewer associated side effects than traditional oncology treatments.

Key Points: 
  • High target affinity and specificity of CTLA4 inhibitors are notably driving the growth.
  • Furthermore, CTLA4 inhibitors work by enhancing the immune system, resulting in comparatively fewer associated side effects than traditional oncology treatments.
  • The global proteasome inhibitors market size is estimated to grow by USD 2.91 billion at a CAGR of 7.48% between 2023 and 2028.
  • The HDAC (histone deacetylase) inhibitors market is estimated to grow at a CAGR of 7.73% between 2022 and 2027.

Therapeutic Vaccines Market Size and Share to Surpass USD 87 Billion by 2035 - Exclusive Report by Roots Analysis

Retrieved on: 
Tuesday, January 9, 2024
Neurological disorder, Patient, Therapy, Research, Cancer, Glioblastoma, ALS, DNA, Epidemic, Tuberculosis, VB, Myeloid leukemia, Lung cancer, Bill, Fever Dream, Infection, Hepatocellular carcinoma, Immune system, Combination therapy, Epstein–Barr virus, Cervical cancer, California Institute of Technology, Intrathecal administration, HIV, Complex, Malaria, Organization, Merck, Vaccine, Colorectal cancer, OPKO Health, Roche, Anal cancer, Prevalence, Growth, Pharmaceutical industry

LONDON, Jan. 9, 2024 /PRNewswire/ -- The global therapeutic vaccines market is estimated to be worth USD 2 billion in 2023 and is anticipated to reach USD 87 billion by 2035. It is expected to grow at a compounded annual growth rate (CAGR) of 35% during the forecast period from 2023 to 2035.

Key Points: 
  • The therapeutic vaccines market is also driven by the expanding pipeline of therapeutic vaccine candidates in the clinical development stages.
  • Based on the type of vaccine, the therapeutic vaccines market is segmented into antigen vaccines, dendritic vaccines, DNA vaccines, and peptide vaccines.
  • Based on the type of method of vaccine composition, the therapeutic vaccines market is segmented into autologous vaccines, allogeneic vaccines and other methods.
  • Europe will dominate the therapeutic vaccines market and is anticipated to capture 59% of the overall revenue share in 2023.

Therapeutic Vaccines Market Size and Share to Surpass USD 87 Billion by 2035 - Exclusive Report by Roots Analysis

Retrieved on: 
Tuesday, January 9, 2024
Neurological disorder, Patient, Therapy, Research, Cancer, Glioblastoma, ALS, DNA, Epidemic, Tuberculosis, VB, Myeloid leukemia, Lung cancer, Bill, Fever Dream, Infection, Hepatocellular carcinoma, Immune system, Combination therapy, Epstein–Barr virus, Cervical cancer, California Institute of Technology, Intrathecal administration, HIV, Complex, Malaria, Organization, Merck, Vaccine, Colorectal cancer, OPKO Health, Roche, Anal cancer, Prevalence, Growth, Pharmaceutical industry

LONDON, Jan. 9, 2024 /PRNewswire/ -- The global therapeutic vaccines market is estimated to be worth USD 2 billion in 2023 and is anticipated to reach USD 87 billion by 2035. It is expected to grow at a compounded annual growth rate (CAGR) of 35% during the forecast period from 2023 to 2035.

Key Points: 
  • The therapeutic vaccines market is also driven by the expanding pipeline of therapeutic vaccine candidates in the clinical development stages.
  • Based on the type of vaccine, the therapeutic vaccines market is segmented into antigen vaccines, dendritic vaccines, DNA vaccines, and peptide vaccines.
  • Based on the type of method of vaccine composition, the therapeutic vaccines market is segmented into autologous vaccines, allogeneic vaccines and other methods.
  • Europe will dominate the therapeutic vaccines market and is anticipated to capture 59% of the overall revenue share in 2023.

Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Pat

Retrieved on: 
Wednesday, December 13, 2023
Patient, ALT, Clutch (eggs), Febrile neutropenia, Hypokalemia, Cardiac arrest, Autoimmune disease, Pneumonia, AZA, TP53, MCR, Anemia, CRi, Fatigue, Disease, Amiodarone, IRR, Clinical trial, Cancer, Morphology, Arrhythmia, ASH, Neutrophil, Combination therapy, Chondrocalcinosis, Observation, Hypoxia, Poster, Safety, AML, Pharmaceutical industry

AUSTIN, TX & DURHAM, NC, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced initial topline dose-expansion data from its ongoing Phase 1A/B clinical trial of SL-172154 in combination with AZA in frontline HR-MDS and TP53m AML patients. Initial data from the dose-expansion cohorts build on the complete dose-escalation data featured in a poster presentation on December 11, 2023 at the 65th ASH Annual Meeting.

Key Points: 
  • That patient remains disease free.” said Dr. Lini Pandite, MBChB, M.B.A., Chief Medical Officer of Shattuck.
  • TP53m AML: In 11 evaluable patients with previously untreated TP53m AML, two patients achieved a CR.
  • Safety: Preliminary data suggest that SL-172154 has an acceptable safety and tolerability profile in combination with azacitidine.
  • To listen to the live webcast, please visit the Investor Relations page of the Shattuck Labs website here .